| Description |
1 online resource (xii, 577 pages) : illustrations |
| Series |
Handbook of experimental pharmacology ; v. 202 |
|
Handbook of experimental pharmacology ; v. 202.
|
| Contents |
880-01 Machine generated contents note: 1. Introduction / Christopher Chapple -- 1.1. Innervation / Christopher Chapple -- 1.2. Sphincteric Mechanisms / Christopher Chapple -- 1.3. Lower Urinary Tract Symptoms / Christopher Chapple -- 1.4. Urodynamic Parameters / Christopher Chapple -- References / Christopher Chapple -- 1. Introduction / Marcus J. Drake / Brian A. Parsons -- 2. The Problem / Marcus J. Drake / Brian A. Parsons -- 3. Pathophysiology of OAB / Marcus J. Drake / Brian A. Parsons -- 4. Current Management of OAB / Marcus J. Drake / Brian A. Parsons -- 5. Importance of Animal Models / Marcus J. Drake / Brian A. Parsons -- 6. Difficulties Interpreting Results from Studies Using Animal Models / Marcus J. Drake / Brian A. Parsons -- 6.1. The Difficulty in Developing Animal Models of OAB / Marcus J. Drake / Brian A. Parsons -- 7. Animal Models of OAB / Marcus J. Drake / Brian A. Parsons -- 7.1. Peripheral Versus Central Models / Marcus J. Drake / Brian A. Parsons |
|
880-01/(S Contents note continued: 2.2. Specific Formulations in OAB / Cees Korstanje / Walter Krauwinkel -- 2.3. Urinary Excretion as Targeting Mechanism in Bladder Diseases / Cees Korstanje / Walter Krauwinkel -- 2.4. Intravesical Administration / Walter Krauwinkel / Cees Korstanje -- 2.5. Other Ways to Manipulate Drug Distribution / Cees Korstanje / Walter Krauwinkel -- 3. Conclusions / Cees Korstanje / Walter Krauwinkel -- References / Walter Krauwinkel / Cees Korstanje -- 1. Introduction / Yoshihiko Ito / Shizuo Yamada -- 1.1.α1Adrenoceptor Subtypes / Shizuo Yamada / Yoshihiko Ito -- 1.2. Localization in the Urinary Tract / Shizuo Yamada / Yoshihiko Ito -- 2. Pharmacology of αAdrenoceptor Antagonists / Shizuo Yamada / Yoshihiko Ito -- 2.1. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms / Shizuo Yamada / Yoshihiko Ito -- 2.2.ai-Adrenoceptor Antagonists / Shizuo Yamada / Yoshihiko Ito -- 3. Prostate / Shizuo Yamada / Yoshihiko Ito |
|
Note continued: 7.2. Induced Hypersensitivity/Inflammatory Models / Marcus J. Drake / Brian A. Parsons -- 7.3. Bladder Outlet Obstruction Model / Marcus J. Drake / Brian A. Parsons -- 7.4. Spontaneous Hypertensive Rat / Marcus J. Drake / Brian A. Parsons -- 7.5. The Hyperlipidaemic Rat / Marcus J. Drake / Brian A. Parsons -- 7.6. Neurological Models / Marcus J. Drake / Brian A. Parsons -- 7.7. Transgenic Animal Models / Marcus J. Drake / Brian A. Parsons -- 8. Conclusions / Marcus J. Drake / Brian A. Parsons -- References / Marcus J. Drake / Brian A. Parsons -- 1. Introduction / Margot S. Damaser / Hai-Hong Jiang -- 2. Methods of Determining SUI in Animal Models / Margot S. Damaser / Hai-Hong Jiang -- 2.1. Sneeze Testing / Margot S. Damaser / Hai-Hong Jiang -- 2.2. Manual LPP Testing / Margot S. Damaser / Hai-Hong Jiang -- 2.3. Vertical Tilt Table LPP Testing / Margot S. Damaser / Hai-Hong Jiang -- 2.4. Electrical Stimulation LPP Testing / Margot S. Damaser / Hai-Hong Jiang |
|
Note continued: 2.5. Urethral Closure Pressure Testing / Margot S. Damaser / Hai-Hong Jiang -- 3. SUI Animal Models / Margot S. Damaser / Hai-Hong Jiang -- 3.1. Models Simulating Childbirth Injury / Margot S. Damaser / Hai-Hong Jiang -- 3.2. Models Simulating Anatomic Support Damage / Margot S. Damaser / Hai-Hong Jiang -- 3.3. Models Simulating Intrinsic Urethra Deficit / Margot S. Damaser / Hai-Hong Jiang -- 4. Treatment Testing on SUI Animal Models / Margot S. Damaser / Hai-Hong Jiang -- 4.1. Pharmacological Therapy Testing / Margot S. Damaser / Hai-Hong Jiang -- 4.2. Sling Surgical Procedures / Margot S. Damaser / Hai-Hong Jiang -- 4.3. Cell-Based Therapy Testing / Margot S. Damaser / Hai-Hong Jiang -- 5. Summary and Perspective on SUI Animal Models / Margot S. Damaser / Hai-Hong Jiang -- References / Margot S. Damaser / Hai-Hong Jiang -- 1. Introduction / J. Paul Hieble -- 2. Measurement of Prostatic Smooth Muscle Tone / J. Paul Hieble |
|
Note continued: 4.3. Effect of Sacral Neuromodulation in Fowler's Syndrome / Derek J. Griffiths -- 4.4. Ice Water (Bladder Cooling) Test / Derek J. Griffiths -- 5. Overactive Bladder Syndrome: Urge Incontinence, Urgency, and Detrusor Overactivity / Derek J. Griffiths -- 5.1. Overactive Bladder: Symptoms and Urodynamics / Derek J. Griffiths -- 5.2. Urgency / Derek J. Griffiths -- 5.3. Detrusor Overactivity / Derek J. Griffiths -- 5.4. Effect of Sacral Neuromodulation in Urge Incontinence / Derek J. Griffiths -- 5.5. Effect of Biofeedback Therapy on Urge Incontinence / Derek J. Griffiths -- 6. Conclusion / Derek J. Griffiths -- References / Derek J. Griffiths -- 1. Introduction / Gert Holstege / Jonathan M. Beckel -- 2. The Anatomy and Innervation of the Lower Urinary Tract / Gert Holstege / Jonathan M. Beckel -- 2.1. The Gross Anatomy of the Lower Urinary Tract / Gert Holstege / Jonathan M. Beckel |
|
Note continued: 2.2. Peripheral Innervation of the Lower Urinary Tract / Gert Holstege / Jonathan M. Beckel -- 2.3. Central Circuits Controlling the Lower Urinary Tract / Gert Holstege / Jonathan M. Beckel -- 2.4. Higher Brain Centers Involved in Voluntary Voiding / Gert Holstege / Jonathan M. Beckel -- 3. Conclusions / Gert Holstege / Jonathan M. Beckel -- References / Gert Holstege / Jonathan M. Beckel -- 1. Introduction / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 1.1. Sex Differences / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 1.2. Species Differences / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 1.3. Embryology / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 2. Anatomy of the Human LUT and Pelvic Floor / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner |
|
Note continued: 2.1. The Urethra and Its Accessory Glands / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 2.2. The Human Pelvic Floor / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 3. Anatomy and Development of the Rodent LUT and "Pelvic Floor" / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 3.1. The Components of the Rodent LUT / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 3.2. The Muscles of the Rodent LUT / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 3.3. The Pelvic Floor Muscles in the Mouse / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- References / Wisuit Pradidarcheep / Wouter H. Lamers / Noshir F. Dabhoiwala / Christian Wallner -- 1. Introduction / Gert Holstege / Jonathan M. Beckel |
|
Note continued: 2. Neural Circuits Controlling the Lower Urinary Tract / Gert Holstege / Jonathan M. Beckel -- 2.1. The Storage Reflex / Gert Holstege / Jonathan M. Beckel -- 2.2. Voiding Reflexes / Gert Holstege / Jonathan M. Beckel -- 3. The Role of the Brain in Voluntary Voiding / Gert Holstege / Jonathan M. Beckel -- 3.1. The Anterior Cingulate Gyrus / Gert Holstege / Jonathan M. Beckel -- 3.2. Prefrontal Cortex / Jonathan M. Beckel / Gert Holstege -- 4. Central Nervous System Pharmacology Controlling Micturition / Jonathan M. Beckel / Gert Holstege -- 5. Central Causes of Pathophysiology of the Lower Urinary Tract / Jonathan M. Beckel / Gert Holstege -- 5.1. Spinal Cord Transection / Jonathan M. Beckel / Gert Holstege -- 5.2. Urge Urinary Incontinence / Gert Holstege / Jonathan M. Beckel -- 6. Conclusions / Gert Holstege / Jonathan M. Beckel -- References / Gert Holstege / Jonathan M. Beckel -- 1. Introduction / Anthony J. Kanai -- 2. Afferent Recordings / Anthony J. Kanai |
|
Note continued: 2.1. Multi- and Single-Unit Recordings / Anthony J. Kanai -- 2.2. Patch Clamp Recording / Anthony J. Kanai -- 2.3. Afferent Recording and Optical Mapping / Anthony J. Kanai -- 3. Afferent Nerve Localization Within the Bladder Wall / Anthony J. Kanai -- 3.1. Peripheral and Central Pathways / Anthony J. Kanai -- 3.2. Myelinated AS-and Unmyelinated C-Fibers / Anthony J. Kanai -- 3.3. Chemo-, Mechano-, and Thermo-Sensitivity / Anthony J. Kanai -- 3.4. Mucosal, Muscle, and Serosal Afferents / Anthony J. Kanai -- 3.5. Pelvic Organ Cross Innervation / Anthony J. Kanai -- 4. Receptors on Afferent Neurons / Anthony J. Kanai -- 4.1. Vanilloids (Table 2) / Anthony J. Kanai -- 4.2. Purinergics / Anthony J. Kanai -- 4.3. Muscarinics / Anthony J. Kanai -- 4.4. Other Receptors / Anthony J. Kanai -- 5. Afferent Adaptation / Anthony J. Kanai -- 5.1. Peripheral and Central Afferent Sensitization / Anthony J. Kanai -- 5.2. Myogenic Enhancement of Afferent Firing / Anthony J. Kanai |
|
Note continued: 6. New Pharmacological Approaches / Anthony J. Kanai -- 7. Conclusion / Anthony J. Kanai -- References / Anthony J. Kanai -- 1. Anatomy and Barrier Function of the Urothelium / Lori A. Birder -- 2. Urothelial Heterogeneity / Lori A. Birder -- 3. Evidence Suggesting a Role for Urothelial Cells in Visceral Sensation / Lori A. Birder -- 4. Involvement of the Urothelium in "Sensing" Chemical and Mechanical Stimuli / Lori A. Birder -- 5. Urothelial Sensor Targets and Mediators / Lori A. Birder -- 5.1. ATP and Purinergic Receptors / Lori A. Birder -- 5.2. TRPV1 Channels / Lori A. Birder -- 5.3. Additional TRP Channels / Lori A. Birder -- 5.4. Nicotinic and Muscarinic Acetylcholine Receptors / Lori A. Birder -- 5.5. Estrogen and Estrogen Receptors / Lori A. Birder -- 5.6. Adrenergic Receptors / Lori A. Birder -- 5.7. Nitric Oxide / Lori A. Birder -- 6. Pathology-Induced Urothelial Plasticity and Effect on Barrier Function / Lori A. Birder |
|
Note continued: 7. Clinical Significance of the Sensory Web / Lori A. Birder -- 8. Conclusions: Potential Clinical Implications / Lori A. Birder -- References / Lori A. Birder -- 1. ICC in the Urinary Tract / Karen D. McCloskey -- 2. Nomenclature / Karen D. McCloskey -- 3. Urinary Bladder / Karen D. McCloskey -- 3.1. Location and Morphology of Bladder ICC / Karen D. McCloskey -- 3.2. Physiological Properties of Bladder ICC / Karen D. McCloskey -- 3.3. Clinical Significance of Bladder ICC / Karen D. McCloskey -- 4. Urethra / Karen D. McCloskey -- 4.1. Location and Morphology of ICC in the Urethral Wall / Karen D. McCloskey -- 4.2. Physiological Properties of Urethral ICC / Karen D. McCloskey -- 4.3. Functional Role of Urethral ICC / Karen D. McCloskey -- 5. Upper Urinary Tract: Renal Pelvis and Ureter / Karen D. McCloskey -- 5.1. Location and Morphology of ICC in the Upper Urinary Tract / Karen D. McCloskey |
|
Note continued: 5.2. Physiological Properties of Upper Urinary Tract ICC / Karen D. McCloskey -- 5.3. Functional Implications of ICC in the Upper Urinary Tract / Karen D. McCloskey -- 6. Future Perspectives for Urinary Tract ICC / Karen D. McCloskey -- References / Karen D. McCloskey -- 1. Introduction to Gene Therapy / George J. Christ -- 2. Current Clinical Applications of Gene Therapy / George J. Christ -- 3. The Current Status of Gene Therapy for the Lower Urinary Tract / George J. Christ -- 4. Preclinical Investigations of Gene Therapy for the Lower Urinary Tract: A Variety of Targets and Possibilities / George J. Christ -- 5. Tuning Gene Therapy for the Lower Urinary Tract / George J. Christ -- 6. Summary and Conclusions / George J. Christ -- References / George J. Christ -- 1. Introduction / Walter Krauwinkel / Cees Korstanje -- 2. Mechanisms of Drug Targeting / Cees Korstanje / Walter Krauwinkel -- 2.1. Prodrugs in OAB / Walter Krauwinkel / Cees Korstanje |
|
Note continued: 3.1.mRNA Expression / Shizuo Yamada / Yoshihiko Ito -- 3.2. Protein Expression / Shizuo Yamada / Yoshihiko Ito -- 3.3. Functions / Shizuo Yamada / Yoshihiko Ito -- 4. Urethra / Shizuo Yamada / Yoshihiko Ito -- 4.1.mRNA and Protein Expression / Shizuo Yamada / Yoshihiko Ito -- 4.2. In Vitro and In Vivo Effects / Shizuo Yamada / Yoshihiko Ito -- 5. Bladder / Shizuo Yamada / Yoshihiko Ito -- 5.1.mRNA Expression / Shizuo Yamada / Yoshihiko Ito -- 5.2. Protein Expression / Yoshihiko Ito / Shizuo Yamada -- 5.3. Functions / Yoshihiko Ito / Shizuo Yamada -- 6. Ureter / Yoshihiko Ito / Shizuo Yamada -- 6.1.mRNA and Protein Expression / Yoshihiko Ito / Shizuo Yamada -- 6.2. In Vitro and In Vivo Effects / Yoshihiko Ito / Shizuo Yamada -- 7. Central Nervous System / Yoshihiko Ito / Shizuo Yamada -- 8. Conclusion / Yoshihiko Ito / Shizuo Yamada -- References / Yoshihiko Ito / Shizuo Yamada -- 1. Introduction / Martin C. Michel -- 2. Methodological Aspects / Martin C. Michel |
|
Note continued: 3. Ureter / Martin C. Michel -- 4. Bladder / Martin C. Michel -- 5. Prostate / Martin C. Michel -- 6. Urethra / Martin C. Michel -- 7. Drugs in Clinical Development / Martin C. Michel -- 8. Conclusions / Martin C. Michel -- References / Martin C. Michel -- 1. Introduction / K.E. Andersson -- 1.1. Muscarinic Acetylcholine Receptors / K.E. Andersson -- 2. Bladder / K.E. Andersson -- 2.1. Cholinergic Nerves / K.E. Andersson -- 2.2. Muscarinic Acetylcholine Receptors / K.E. Andersson -- 2.3. Receptor Distribution and Function / K.E. Andersson -- 2.4. Receptor Changes in Disease / K.E. Andersson -- 3. Urethra / K.E. Andersson -- 3.1. Cholinergic Nerves / K.E. Andersson -- 3.2. Receptor Distribution and Function / K.E. Andersson -- 3.3. Changes in Disease / K.E. Andersson -- 4. Prostate / K.E. Andersson -- 4.1. Cholinergic Nerves / K.E. Andersson -- 4.2. Muscarinic Receptors / K.E. Andersson -- 4.3. Distribution and Function / K.E. Andersson |
|
Note continued: 4.4. Changes in Disease / K.E. Andersson -- 5. Ureter / K.E. Andersson -- 5.1. Cholinergic Nerves / K.E. Andersson -- 5.2. Muscarinic Receptors / K.E. Andersson -- 5.3. Distribution and Function / K.E. Andersson -- 5.4. Receptor Changes in Disease / K.E. Andersson -- 6. Muscarinic Receptor Agonists / K.E. Andersson -- 7. Muscarinic Receptor Antagonists / K.E. Andersson -- 8. Summary and Perspectives / K.E. Andersson -- References / K.E. Andersson -- 1. General Characteristics of the TRPV 1 Receptor / Ana Charrua / Francisco Cruz / António Avelino -- 1.1. Localization of TRPV 1 Protein in Lower Urinary Tract / Francisco Cruz / António Avelino / Ana Charrua -- 1.2. The Role of TRPV 1 on Lower Urinary Tract Function and Dysfunction / Ana Charrua / Francisco Cruz / António Avelino -- 1.3. TRPV 1 Regulatory Mechanisms During LUT Inflammation / Ana Charrua / Francisco Cruz / António Avelino |
|
Note continued: 1.4. Mechanisms of TRPV1 Desensitization / Ana Charrua / Francisco Cruz / António Avelino -- 1.5. TRPV1 Antagonists / Ana Charrua / Francisco Cruz / António Avelino -- 1.6. Clinical Perspective of TRPV1 Targeting / Ana Charrua / Francisco Cruz / António Avelino -- 2. General Characteristics of Botulinum Toxin / Ana Charrua / Francisco Cruz / António Avelino -- 2.1. BoNT Mechanism of Action / Ana Charrua / Francisco Cruz / António Avelino -- 2.2. BoNT/A and the Urinary Bladder / Ana Charrua / Francisco Cruz / António Avelino -- 2.3. BoNT/A and the Prostate / Ana Charrua / Francisco Cruz / António Avelino -- 2.4. Clinical Implications in the Usage of BoNT/A / Ana Charrua / Francisco Cruz / António Avelino -- 3. Future Directions / Ana Charrua / Francisco Cruz / António Avelino -- References / Ana Charrua / Francisco Cruz / António Avelino -- 1. Introduction / K.L. Brain / A.F. Brading -- 2. Potassium Channels / A.F. Brading / K.L. Brain |
|
Note continued: 2.1.4TM Channels / K.L. Brain / A.F. Brading -- 2.2.2TM Channels / K.L. Brain / A.F. Brading -- 2.3.6TM Channels / K.L. Brain / A.F. Brading -- 3. TRP Channels / K.L. Brain / A.F. Brading -- 4. Ca2+ Channels / K.L. Brain / A.F. Brading -- 4.1. Store-Operated Ca2+ Channels / K.L. Brain / A.F. Brading -- 5. CF Channels / K.L. Brain / A.F. Brading -- 5.1. Types of Cl- Channels and Their Functions / K.L. Brain / A.F. Brading -- 6. Na+ Channels / K.L. Brain / A.F. Brading -- 7. Ion Channels in Urinary Tract Smooth Muscles / K.L. Brain / A.F. Brading -- 7.1. Distribution of Ion Channels / K.L. Brain / A.F. Brading -- 7.2. Potential Benefit of Modulating Ion Channels / A.F. Brading / K.L. Brain -- 8. Conclusion / K.L. Brain / A.F. Brading -- 8.1.A Speculative Approach / K.L. Brain / A.F. Brading -- References / K.L. Brain / A.F. Brading -- 1. Introduction: Micturition Overview and Anatomy of Lower Urinary Tract / Margaret A. Vizzard / Lauren Arms |
|
Note continued: 1.1. Neural Control of Micturition / Margaret A. Vizzard / Lauren Arms -- 1.2. Neurochemistry and Morphology of Afferent and Spinal Pathways to the Urogenital Tract / Margaret A. Vizzard / Lauren Arms -- 1.3. Neurochemical Plasticity in the LUT with Bladder Inflammation, Neural Injury, or Disease / Margaret A. Vizzard / Lauren Arms -- 2. PACAP/VIP and Associated Receptors Signaling in the LUT / Margaret A. Vizzard / Lauren Arms -- 2.1. PACAP/Receptors in Micturition Reflex Pathways / Margaret A. Vizzard / Lauren Arms -- 2.2. PACAP Expression in Bladder Afferent Pathways and Regulation by CYP-Induced Cystitis / Margaret A. Vizzard / Lauren Arms -- 2.3. PACAP/VIP Receptor Expression in LUT and Modulation with Cystitis / Margaret A. Vizzard / Lauren Arms -- 2.4. PACAP in Micturition Reflexes and Modulation After Spinal Cord Injury / Margaret A. Vizzard / Lauren Arms |
|
Note continued: 2.5. PACAP and VIP Expression and Effects on Major Pelvic Ganglion Neurons / Margaret A. Vizzard / Lauren Arms -- 2.6. PACAP Null lax Exhibit Altered Bladder Function and Somatic Sensitivity / Margaret A. Vizzard / Lauren Arms -- 2.7. VIP/Receptors and Micturition Reflex Pathways / Margaret A. Vizzard / Lauren Arms -- 2.8. PACAP-Mediated ATP Release from Cultured, Rat Urothelium / Margaret A. Vizzard / Lauren Arms -- 3. Tachykinins and Calcitonin-Gene Related Peptide in Micturition Reflex Pathways / Margaret A. Vizzard / Lauren Arms -- 3.1. Tachykinins and CGRP in Micturition Reflex Pathways and Regulation with Inflammation, Injury, or Disease / Margaret A. Vizzard / Lauren Arms -- 3.2. SP and CGRP Plasticity in LUT Pathways with CYP-Induced Cystitis / Margaret A. Vizzard / Lauren Arms -- 4. Role of Neurotrophic Factors in Neuropeptide Expression in Micturition Pathways after CYP-Induced Cystitis / Margaret A. Vizzard / Lauren Arms |
|
Note continued: 5. Bradykinin/Receptors System in Micturition Reflex Pathways / Margaret A. Vizzard / Lauren Arms -- 5.1. Bradykinin/Receptors in Cystitis / Margaret A. Vizzard / Lauren Arms -- 6. Endothelin/Receptors System in LUT Pathways / Margaret A. Vizzard / Lauren Arms -- 6.1. Endothelin/Receptor System in Bladder Outlet Obstruction and Spinal Cord Transection / Margaret A. Vizzard / Lauren Arms -- 6.2. Endothelin/Receptor Systems in the Urethra / Lauren Arms / Margaret A. Vizzard -- 7. Perspectives / Margaret A. Vizzard / Lauren Arms -- References / Margaret A. Vizzard / Lauren Arms -- 1. Introduction / Michael R. Ruggieri, Sr -- 2. Cannabinoids and Their Receptors in the Urinary Tract / Michael R. Ruggieri, Sr -- 2.1. Endogenous Cannabinoids and Metabolism / Michael R. Ruggieri, Sr -- 2.2. Drugs Acting on Cannabinoid Receptors / Michael R. Ruggieri, Sr |
|
Note continued: 2.3. Cellular Location of Cannabinoid Receptors in the Urinary Tract and CNS Areas Involved in Control of Urinary Tract Function / Michael R. Ruggieri, Sr -- 2.4. Effects of Cannabinoid Receptors on Normal Urinary Bladder Function / Michael R. Ruggieri, Sr -- 2.5. Cannabinoid Effects on Inflamed Bladder / Michael R. Ruggieri, Sr -- 2.6. Clinical Studies of Cannabinoids for Control of Bladder Dysfunction in Multiple Sclerosis / Michael R. Ruggieri, Sr -- 3. Conclusions / Michael R. Ruggieri, Sr -- References / Michael R. Ruggieri, Sr -- 1. Introduction / Hashim Hashim / Sailaja Pisipati -- 2. Vasopressin Receptors / Hashim Hashim / Sailaja Pisipati -- 2.1. Types of Receptors / Hashim Hashim / Sailaja Pisipati -- 2.2. Distribution / Hashim Hashim / Sailaja Pisipati -- 3. Basic Pharmacology / Hashim Hashim / Sailaja Pisipati -- 3.1.V1 Receptor Effector Coupling / Hashim Hashim / Sailaja Pisipati |
|
Note continued: 3.2.V2 Receptor Effector Coupling / Hashim Hashim / Sailaja Pisipati -- 4. Functions of Vasopressin / Hashim Hashim / Sailaja Pisipati -- 4.1. Renal Actions of Vasopressin / Hashim Hashim / Sailaja Pisipati -- 4.2. Non-Renal Actions of Vasopressin / Hashim Hashim / Sailaja Pisipati -- 5. Vasopressin: Like Peptides and Their Clinical Utility / Hashim Hashim / Sailaja Pisipati -- 5.1. Urological Applications / Hashim Hashim / Sailaja Pisipati -- 5.2. Non-Urological Applications of Vasopressin and Agonists / Hashim Hashim / Sailaja Pisipati -- 6. Vasopressin Antagonists / Hashim Hashim / Sailaja Pisipati -- 6.1. Clinical Utility of Vasopressin Receptor Antagonists / Hashim Hashim / Sailaja Pisipati -- 7. Mutations / Hashim Hashim / Sailaja Pisipati -- 8. Conclusion / Hashim Hashim / Sailaja Pisipati -- References / Hashim Hashim / Sailaja Pisipati -- 1. Introduction / Debra A. Cockayne / Anthony P.D.W. Ford |
|
Note continued: 1.1. Purinergic Efferent and Afferent Function / Anthony P.D.W. Ford / Debra A. Cockayne -- 1.2. ATP: The Ubiquitous Signaling Factor / Debra A. Cockayne / Anthony P.D.W. Ford -- 1.3.P2X Receptors / Debra A. Cockayne / Anthony P.D.W. Ford -- 2. ATP, Urinary Function, and Dysfunction / Debra A. Cockayne / Anthony P.D.W. Ford -- 2.1. Evidence of a Role for ATP in the Urinary Tract / Debra A. Cockayne / Anthony P.D.W. Ford -- 2.2.P2X Receptors and Urinary Tract Function / Debra A. Cockayne / Anthony P.D.W. Ford -- 3.P2X Receptors as Therapeutic Targets for Urinary Tract Disorders / Debra A. Cockayne / Anthony P.D.W. Ford -- 3.1.P2X1 Receptor Antagonism / Debra A. Cockayne / Anthony P.D.W. Ford -- 3.2.P2X3 and P2X2/3 Receptor Antagonism / Debra A. Cockayne / Anthony P.D.W. Ford -- 4. Conclusions / Debra A. Cockayne / Anthony P.D.W. Ford -- References / Anthony P.D.W. Ford / Debra A. Cockayne -- 1. Introduction / Markus A. Kuczyk / Stefan Ückert |
|
Note continued: 2. Soluble Guanylyl Cyclase / Markus A. Kuczyk / Stefan Ückert -- 3. Phosphodiesterase Isoenzymes / Markus A. Kuczyk / Stefan Ückert -- 4. Cyclic Nucleotide-Binding Protein Kinases / Markus A. Kuczyk / Stefan Ückert -- 5. Targets for the Pharmacological Modulation of the Cyclic AMP/Cyclic GMP Signaling in the LUT / Stefan Ückert / Markus A. Kuczyk -- 5.1. Prostate / Markus A. Kuczyk / Stefan Ückert -- 5.2. Urinary Bladder / Stefan Ückert / Markus A. Kuczyk -- 5.3. Ureter / Markus A. Kuczyk / Stefan Ückert -- 5.4. Urethra / Stefan Ückert / Markus A. Kuczyk -- 6. Conclusion / Markus A. Kuczyk / Stefan Ückert -- References / Markus A. Kuczyk / Stefan Ückert -- 1. Introduction / Michael E. DiSanto / Xinhua Zhang -- 2. Smooth Muscle Contraction / Michael E. DiSanto / Xinhua Zhang -- 3. Calcium Sensitization / Michael E. DiSanto / Xinhua Zhang -- 3.1. Rho/Rho-Kinase / Michael E. DiSanto / Xinhua Zhang -- 3.2. Rho / Michael E. DiSanto / Xinhua Zhang |
|
Note continued: 3.3. Rho-Kinase / Michael E. DiSanto / Xinhua Zhang -- 3.4. Activation of the Rho/Rho-Kinase Pathway / Xinhua Zhang / Michael E. DiSanto -- 3.5. Effectors of the Rho/Rho-Kinase Pathway / Xinhua Zhang / Michael E. DiSanto -- 4. Rho-Kinase in Dysfunctional Bladder Contractility / Xinhua Zhang / Michael E. DiSanto -- 4.1. Partial Bladder Outlet Obstruction / Michael E. DiSanto / Xinhua Zhang -- 4.2. Diabetic Bladder / Xinhua Zhang / Michael E. DiSanto -- 4.3. Hypertension-Associated Bladder Dysfunction / Xinhua Zhang / Michael E. DiSanto -- 4.4. Hormonal Regulation of Rho-Kinase / Xinhua Zhang / Michael E. DiSanto -- 4.5. The Aging Bladder / Xinhua Zhang / Michael E. DiSanto -- 5. Rho-Kinase in Ureteral Contractility / Xinhua Zhang / Michael E. DiSanto -- 6. Non SM Contractility Effects of Rho-Kinase in the Bladder and Ureter / Michael E. DiSanto / Xinhua Zhang -- 7. Conclusions / Michael E. DiSanto / Xinhua Zhang -- References / Michael E. DiSanto / Xinhua Zhang |
| Summary |
The basic anatomy and physiology of the urinary tract, the validity of animal models and other methodological considerations as well as a range of potential therapeutic targets are comprehensively reviewed by leading international experts, making this a unique reference source for basic scientists and research-minded clinicians alike |
| Analysis |
farmacologie |
|
pharmacology |
|
toxicologie |
|
toxicology |
|
fysiologie |
|
physiology |
|
geneeskunde |
|
medicine |
|
urinestelsel |
|
urinary system |
|
biomedische wetenschappen |
|
biomedicine |
|
Medicine (General) |
|
Geneeskunde (algemeen) |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Urinary organs.
|
|
Urinary organs -- Diseases.
|
|
Urinary organs -- Abnormalities
|
|
Urinary Tract Physiological Phenomena
|
|
Urologic Diseases
|
|
Urinary Tract
|
|
HEALTH & FITNESS -- Diseases -- Genitourinary & STDs.
|
|
MEDICAL -- Urology.
|
|
Urinary organs
|
|
Urinary organs -- Abnormalities
|
|
Urinary organs -- Diseases
|
| Form |
Electronic book
|
| Author |
Andersson, Karl-Erik
|
|
Michel, Martin C., 1959-
|
| ISBN |
9783642164996 |
|
3642164994 |
|
9783642164989 |
|
3642164986 |
